Table of Contents
ISRN Gastroenterology
Volume 2012 (2012), Article ID 595968, 16 pages
http://dx.doi.org/10.5402/2012/595968
Review Article

Gastrointestinal Stromal Tumors: A Review of Case Reports, Diagnosis, Treatment, and Future Directions

1Department of Internal Medicine, Nassau University Medical Center, East Meadow, NY 11554, USA
2Department of Gastroenterology, Nassau University Medical Center, East Meadow, NY 11554, USA

Received 13 January 2012; Accepted 5 February 2012

Academic Editors: A. Amedei and C.-T. Shun

Copyright © 2012 Christopher B. Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. P. de Matteo, K. V. Ballman, C. R. Antonescu et al., “Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 373, no. 9669, pp. 1097–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Laurini and J. E. Carter, “Gastrointestinal stromal tumors: a review of the literature,” Archives of Pathology and Laboratory Medicine, vol. 134, no. 1, pp. 134–141, 2010. View at Google Scholar
  3. M. Miettinen and J. Lasota, “Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis,” Archives of Pathology and Laboratory Medicine, vol. 130, no. 10, pp. 1466–1478, 2006. View at Google Scholar · View at Scopus
  4. D. T. Patil and B. P. Rubin, “Gastrointestinal stromal tumor: advances in diagnosis and management,” Archives of Pathology and Laboratory Medicine, vol. 135, no. 10, pp. 1298–1310, 2011. View at Google Scholar
  5. G. D. Demetri, M. von Mehren, C. R. Antonescu et al., “NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors,” JNCCN Journal of the National Comprehensive Cancer Network, vol. 8, supplement 2, pp. S1–S44, 2010. View at Google Scholar · View at Scopus
  6. K. Chandramohan, M. Agarwal, G. Gurjar et al., “Gastrointestinal stromal tumour in Meckel's diverticulum,” World Journal of Surgical Oncology, vol. 5, p. 50, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. G. D. Demetri, R. L. Titton, D. P. Ryan, and C. D. Fletcher, “Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass,” The New England Journal of Medicine, vol. 351, no. 17, pp. 1779–1787, 2004. View at Google Scholar
  8. T. Terada, “Gastrointestinal stromal tumor of the uterus: a case report with genetic analyses of c-kit and PDGFRA genes,” International Journal of Gynecological Pathology, vol. 28, no. 1, pp. 29–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Laperouse, D. Raines, K. Diamond et al., “Gastrointestinal stromal tumors: a case report and review of the literature,” The Journal of the Louisiana State Medical Society, vol. 160, no. 3, pp. 128–134, 2008. View at Google Scholar · View at Scopus
  10. A. W. Gramza, C. L. Corless, and M. C. Heinrich, “Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors,” Clinical Cancer Research, vol. 15, no. 24, pp. 7510–7518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Lasota, M. Jasinski, M. Sarlomo-Rikala, and M. Miettinen, “Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas,” American Journal of Pathology, vol. 154, no. 1, pp. 53–60, 1999. View at Google Scholar · View at Scopus
  12. E. Wardelmann, I. Losen, V. Hans et al., “Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors,” International Journal of Cancer, vol. 106, no. 6, pp. 887–895, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. L. Lux, B. P. Rubin, T. L. Biase et al., “KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors,” American Journal of Pathology, vol. 156, no. 3, pp. 791–795, 2000. View at Google Scholar · View at Scopus
  14. J. Lasota, A. Dansonka-Mieszkowska, L. H. Sobin, and M. Miettinen, “A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential,” Laboratory Investigation, vol. 84, no. 7, pp. 874–883, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Lasota and M. Miettinen, “KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs),” Seminars in Diagnostic Pathology, vol. 23, no. 2, pp. 91–102, 2006. View at Google Scholar
  16. J. Lasota, J. Stachura, and M. Miettinen, “GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology,” Laboratory Investigation, vol. 86, no. 1, pp. 94–100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Scherjon, W. F. Lam, H. Gelderblom, and F. W. Jansen, “Gastrointestinal stromal tumor in pregnancy: a case report,” Case Reports Medicine, vol. 2009, Article ID 456402, 2009. View at Google Scholar
  18. A. Trabelsi, L. B. Yacoub, A. Mtimet et al., “Gastrointestinal stromal tumor of the pancreas: a case report and review of literature,” North American Journal of Medical Sciences, vol. 1, no. 6, pp. 324–326, 2009. View at Google Scholar
  19. S. Papaspyros and K. Papagiannopoulos, “Gastrointestinal stromal tumor masquerading as a lung neoplasm. A case presentation and literature review,” Journal of Cardiothoracic Surgery, vol. 3, no. 31, pp. 1749–8090, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. L. Lin, C. K. Wei, J. K. Chiang, A. L. Chou, C. W. Chen, and C. E. Tseng, “Concomitant gastric carcinoid and gastrointestinal stromal tumors: a case report,” World Journal of Gastroenterology, vol. 14, no. 39, pp. 6100–6103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Efstathios, P. Athanasios, I. Papaconstantinou et al., “Coexistence of gastrointestinal stromal tumor (GIST) and colorectal adenocarcinoma: a case report,” World Journal of Surgical Oncology, vol. 5, p. 96, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Ohtake, N. Kobayashi, S. Kato et al., “Duodenal gastrointestinal stromal tumor resembling a pancreatic neuroendocrine tumor in a patient with neurofibromatosis type I (von Recklinghausen's disease): a case report,” Journal of Medical Case Reports, vol. 4, p. 302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Masoodi, M. Chalkoo, A. Rashid, and I. A. Wani, “Extra luminal colonic gastrointestinal stromal tumor: a case report,” Cases Journal, vol. 2, no. 5, article 7525, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. B. B. Freeman, J. F. Critchlow, S. Cohen, and J. A. Edlow, “Spontaneous intraperitoneal hemorrhage as the initial presentation of a gastrointestinal stromal tumor: a case report,” International Journal of Emergency Medicine, vol. 3, no. 1, pp. 53–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Pinto, G. Ingravallo, E. Cicinelli et al., “Gastrointestinal stromal tumors mimicking gynecological masses on ultrasound: a report of two cases,” Ultrasound in Obstetrics and Gynecology, vol. 30, no. 3, pp. 359–361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. H.-A. Fan, Y.-T. Kung, K.-W. Liu et al., “Gastrointestinal stromal tumor of the rectum: a case report,” Journal of Society of Colon and Rectal Surgeons, vol. 22, pp. 45–49, 2011. View at Google Scholar
  27. X. L. Luo, D. Liu, J. J. Yang, M. W. Zheng, J. Zhang, and X. D. Zhou, “Primary gastrointestinal stromal tumor of the liver: a case report,” World Journal of Gastroenterology, vol. 15, no. 29, pp. 3704–3707, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. A. F. Yucel, H. Sunar, A. Hut et al., “Gastrointestinal stromal tumors with unusual localization: report of three cases with a brief literature review,” Case Reports in Gastroenterology, vol. 4, no. 2, pp. 250–260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. C. K. Lee, A. Hadley, K. Desilva, G. Smith, and D. Goldstein, “When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis,” World Journal of Surgical Oncology, vol. 7, p. 8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Theodosopoulos, D. Dellaportas, V. Psychogiou et al., “Synchronous gastric adenocarcinoma and gastrointestinal stromal tumor (GIST) of the stomach: a case report,” World Journal of Surgical Oncology, vol. 9, p. 60, 2011. View at Google Scholar
  31. S. Ulusan, Z. Koc, and F. Kayaselcuk, “Spontaneously ruptured gastrointestinal stromal tumor with pelvic abscess: a case report and review,” Gastroenterolgy Research Journal, vol. 2, no. 6, pp. 361–363, 2009. View at Google Scholar
  32. Y. Sakamoto, J. Yamamoto, H. Takahashi et al., “Segmental resection of the third portion of the duodenum for a gastrointestinal stromal tumor: a case report,” Japanese Journal of Clinical Oncology, vol. 33, no. 7, pp. 364–366, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Abdel-Ghaffar, “Large gastrointestinal stromal tumor size does not imply early recurrence,” International Medical Case Reports Journal, vol. 3, no. 1, pp. 13–17, 2010. View at Google Scholar · View at Scopus
  34. T. Todoroki, T. Sano, S. Sakurai et al., “Primary omental Gastrointestinal stromal tumor (GIST),” World Journal of Surgical Oncology, vol. 5, p. 66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. A. K. Dhull, V. Kaushal, R. Dhankhar, R. Atri, H. Singh, and N. Marwah, “The inside mystery of jejunal gastrointestinal stromal tumor: a rare report and review of the literature,” Case Reports in Oncological Medicine, vol. 2011, Article ID 985242, 4 pages, 2011. View at Publisher · View at Google Scholar
  36. C. Dickhoff, R. J. Leguit, J. F. Slors, W. L. Vervenne, and W. A. Bemelman, “Giant rectal gastrointestinal stromal tumors: a report of two cases,” Case Reports in Gastroenterology, vol. 2, no. 1, pp. 54–69, 2008. View at Google Scholar
  37. H. Takeuchi, T. Matsumoto, T. Kusumoto, Y. Yoshikawa, and Y. Muto, “Duodenal gastrointestinal stromal tumor treated by wedge resection in a patient with neurofibromatosis type 1: report of a case and review of the Japanese literature,” Case Reports in Gastroenterology, vol. 3, no. 3, pp. 343–349, 2009. View at Google Scholar
  38. T. Tahara, T. Shibata, M. Nakamura et al., “Gastrointestinal stromal tumor of the stomach with narrow stalk-like based, uneven protruding appearance presenting with severe acute anemia despite small size,” Case Reports in Gastroenterology, vol. 4, no. 1, pp. 111–117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Kitagawa, T. Koh, N. Nakagawa et al., “Gastrointestinal stromal tumor in a patient with neurofibromatosis: abscess formation in the tumor leading to bacteremia and seizure,” Case Reports in Gastroenterology, vol. 4, no. 3, pp. 435–442, 2010. View at Google Scholar
  40. K. Takakura, M. Kajihara, S. Sasaki et al., “Use of balloon enteroscopy in preoperative diagnosis of neurofibromatosis-associated gastrointestinal stromal tumours of the small bowel: a case report,” Case Reports in Gastroenterology, vol. 5, no. 2, pp. 308–314, 2011. View at Google Scholar
  41. M. Varras, N. Vlachakos, C. Akrivis, T. Vasilakaki, and E. Skafida, “Malignant gastrointestinal stromal tumor presenting with hemoperitoneum in puerperium: report of a case with review of the literature,” World Journal of Surgical Oncology, vol. 8, p. 95, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Caterino, L. Lorenzon, N. Petrucciani et al., “Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients,” World Journal of Surgical Oncology, vol. 9, p. 13, 2011. View at Publisher · View at Google Scholar
  43. S. C. Abraham, “Distinguishing gastrointestinal stromal tumors from their mimics: an update,” Advances in Anatomic Pathology, vol. 14, no. 3, pp. 178–188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Agarwal and M. Robson, “Inherited predisposition to gastrointestinal stromal tumor,” Hematology/Oncology Clinics of North America, vol. 23, no. 1, pp. 1–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Aidan Carney, “Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence,” Mayo Clinic Proceedings, vol. 74, no. 6, pp. 543–552, 1999. View at Google Scholar · View at Scopus
  46. J. A. Carney and C. A. Stratakis, “Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad,” American Journal of Medical Genetics, vol. 108, no. 2, pp. 132–139, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Takazawa, S. Sakurai, Y. Sakuma et al., “Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease),” American Journal of Surgical Pathology, vol. 29, no. 6, pp. 755–763, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Miettinen and J. Lasota, “Gastrointestinal stromal tumors: pathology and prognosis at different sites,” Seminars in Diagnostic Pathology, vol. 23, no. 2, pp. 70–83, 2006. View at Google Scholar
  49. L. Zhang, T. C. Smyrk, W. F. Young, C. A. Stratakis, and J. A. Carney, “Gastric stromal tumors in carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: Findings in 104 cases,” American Journal of Surgical Pathology, vol. 34, no. 1, pp. 53–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. K. M. Kim, D. W. Kang, W. S. Moon et al., “PKCtheta expression in gastrointestinal stromal tumor,” Modern Pathology, vol. 19, no. 11, pp. 1480–1486, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. W. B. Ou, M. J. Zhu, G. D. Demetri, C. D. M. Fletcher, and J. A. Fletcher, “Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors,” Oncogene, vol. 27, no. 42, pp. 5624–5634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Y. Blay, S. Bonvalot, P. Casali et al., “Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO,” Annals of Oncology, vol. 16, no. 4, pp. 566–578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Motegi, S. Sakurai, H. Nakayama, T. Sano, T. Oyama, and T. Nakajima, “PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors,” Pathology International, vol. 55, no. 3, pp. 106–112, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. I. Espinosa, C. H. Lee, M. K. Kim et al., “A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors,” American Journal of Surgical Pathology, vol. 32, no. 2, pp. 210–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. R. B. West, C. L. Corless, X. Chen et al., “The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status,” American Journal of Pathology, vol. 165, no. 1, pp. 107–113, 2004. View at Google Scholar · View at Scopus
  56. A. Agaimy, “Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting,” International Journal of Clinical and Experimental Pathology, vol. 3, no. 5, pp. 461–471, 2010. View at Google Scholar · View at Scopus
  57. P. Rutkowski, Z. I. Nowecki, W. Michej et al., “Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor,” Annals of Surgical Oncology, vol. 14, no. 7, pp. 2018–2027, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Patel, “Navigating risk stratification systems for the management of patients with GIST,” Annals of Surgical Oncology, vol. 16, no. 6, pp. 1698–1704, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. L. H. Sobin and C. C. Compton, “TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer,” Cancer, vol. 116, no. 22, pp. 5336–5339, 2010. View at Google Scholar
  60. H. Joensuu, A. Vehtari , J. Riihimäki et al., “Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts,” The Lancet, vol. 13, no. 3, pp. 265–274, 2011. View at Publisher · View at Google Scholar
  61. M. E. Blackstein, J. Y. Blay, C. Corless et al., “Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment,” Canadian Journal of Gastroenterology, vol. 20, no. 3, pp. 157–163, 2006. View at Google Scholar · View at Scopus
  62. R. S. Date, N. A. Stylianides, K. G. Pursnani, J. B. Ward, and M. M. Mughal, “Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective,” World Journal of Surgical Oncology, vol. 6, p. 77, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. J. T. Vetto, “Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs),” Onco Targets and Therapy, vol. 2, pp. 151–159, 2009. View at Google Scholar · View at Scopus
  64. A. Schwandt, L. S. Wood, B. Rini, and R. Dreicer, “Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma,” Onco Targets and Therapy, vol. 2, pp. 51–61, 2009. View at Google Scholar · View at Scopus
  65. B. Billemont, S. Barete, and O. Rixe, “Scrotal cutaneous side effects of sunitinib,” The New England Journal of Medicine, vol. 359, no. 9, pp. 975–976, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Pennacchioli, C. Colombo, M. Berselli, and A. Gronchi, “Update on management of GIST and postsurgical use of imatinib,” Open Access Surgery, vol. 2010, pp. 63–71, 2010. View at Publisher · View at Google Scholar
  67. A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST), Novartis Pharmaceuticals Corporation, New York, NY, USA, 2009.
  68. P. G. Casali, H. Joensuu, J. M. Broto et al., “Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST),” Journal of Clinical Oncology, vol. 28, p. 15s, 2010. View at Google Scholar
  69. M. Montemurro, P. Schöffski, P. Reichardt et al., “Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib,” European Journal of Cancer, vol. 45, no. 13, pp. 2293–2297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. N. P. Shah, F. Y. Lee, R. Luo, Y. Jiang, M. Donker, and C. Akin, “Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis,” Blood, vol. 108, no. 1, pp. 286–291, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. M. M. Schittenhelm, S. Shiraga, A. Schroeder et al., “Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies,” Cancer Research, vol. 66, no. 1, pp. 473–481, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. N. L. Lewis, L. D. Lewis, J. P. Eder et al., “Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers,” Journal of Clinical Oncology, vol. 27, no. 31, pp. 5262–5269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Michael, G. Vlahovic, K. Khamly, K. J. Pierce, F. Guo, and A. J. Olszanski, “Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor,” British Journal of Cancer, vol. 103, no. 10, pp. 1554–1561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Michael, D. Griffith, A. Mckinley, A. Presnell, and A. Ramachandran, Crenolanib (CP-868,596) Inhibits Phosphorylation of the Imatinib-Resistant D842V PDGFRA Activating Mutation Associated with Advanced GIST (Abstract 10012). ASCO meeting.
  75. K. Podar, G. Tonon, M. Sattler et al., “The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 51, pp. 19478–19483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Sarker, R. Molife, T. R. J. Evans et al., “A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors,” Clinical Cancer Research, vol. 14, no. 7, pp. 2075–2081, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. H. S. Nimeiri, R. G. Maki, K. Kasza et al., “Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium,” in Proceedings of the Gastrointestinal Cancers Symposium (GCS '08), Orlando, Fla, USA, January 2008.
  78. S. M. Wilhelm, C. Carter, L. Tang et al., “BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis,” Cancer Research, vol. 64, no. 19, pp. 7099–7109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. L. M. Gava and C. H. I. Ramos, “Human 90 kDa heat shock protein Hsp90 as a target for cancer therapeutics,” Current Chemical Biology, vol. 2009, no. 3, pp. 330–341, 2009. View at Google Scholar
  80. T. Taldone, A. Gozman, R. Maharaj, and G. Chiosis, “Targeting Hsp90: small-molecule inhibitors and their clinical development,” Current Opinion in Pharmacology, vol. 8, no. 4, pp. 370–374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Wang, J. B. Trepe, L. M. Neckers, and G. Giaccon, “STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer,” Current Opinion in Investigational Drugs, vol. 11, no. 12, pp. 1466–1476, 2010. View at Google Scholar
  82. D. A. Proia, K. P. Foley, T. Korbut et al., “Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling,” PLoS One, vol. 6, no. 4, Article ID e18552, 2011. View at Publisher · View at Google Scholar